An observational study in Hypertrophic Cardiomyopathy (HCM), sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Observational
Among 71 studies in Cardiomyopathy, Hypertrophic with a site in China — 30 open to participants now, 43 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · China.
Among the 71 studies in Cardiomyopathy, Hypertrophic with a site in China, this one is the 4th largest by planned enrollment of the 32 observational ones that give a count, is one of 8 that started in 2026, is one of 32 observational ones, reaches primary completion later than 42 of the 42 other live ones, and was the 52nd registered.
363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →30 of the 71 studies in Cardiomyopathy, Hypertrophic with a site in China are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Peking Union Medical College Hospital · Sites in China
Ages 18–85 · Healthy volunteers
SuZhou Sinus Medical Technologies Co.,Ltd · Sites in China
Ages 18–80
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–85
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 7 · Phase 4 3
First in 2011; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,000 is above the median of 259 across 174 observational studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 84 across the 39 interventional studies, 608 across the 32 observational. Of the 21 that completed or were terminated, 5 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 71 have an industry lead sponsor. The 10 most frequent:
Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 100 studies on the registry; 68 are open to participants now.
Second Affiliated Hospital, Zhejiang University, School of Medicine has 3 studies filed under Cardiomyopathy, Hypertrophic — fewer than ten, so there is no comparison to draw.
8 of the studies in Cardiomyopathy, Hypertrophic with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07354646Chinese Academy of Medical Sciences, Fuwai HospitalThe Application of T1 Mapping in Real-World | 2026-12-01 |
| NCT07006493SuZhou Sinus Medical Technologies Co.,LtdREFINE-HCM: Intramyocardial Septal Radiofrequency Ablation for Obstructive Hypertrophic Cardiomyopathy | 2026-12-30 |
| NCT07464132Peking Union Medical College HospitalApplication of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases | 2027-02-17 |
| NCT07846059Bristol-Myers SquibbEvaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy | 2027-03-31 |
| NCT06794710RenJi HospitalEarly Identification and Treatment of Rare Cardiomyopathy Cohorts | 2027-05-30 |
Add all 8 to your calendar (.ics) → With an account.
Among the 71 studies in Cardiomyopathy, Hypertrophic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a prospective cohort study aimed at exploring the baseline characteristics and treatment patterns of the Chinese population with hypertrophic cardiomyopathy (HCM) in real-world settings. The objective is to assess the real-world treatment approaches and longitudinal outcomes in this population.
Patients with hypertrophic cardiomyopathy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosed with hypertrophic cardiomyopathy (HCM) according to the 2023 Guideline for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy, meeting the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients diagnosed with hypertrophic cardiomyopathy (HCM) according to the 2023 Guideline for Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy were consecutively enrolled. These patients received pharmacological, interventional, or surgical treatment based on real-world treatment strategies. Follow-up was conducted to observe patient prognosis and the occurrence of outcome events.
Other: No interventions were applied to the patients.
No interventions were applied to the patients.
Composite Cardiovascular Endpoints
Number of Participants with a composite cardiovascular endpoint consisting of ischemic stroke, heart failure hospitalization, and cardiovascular death
Time frame: 5 years
All-cause mortality
Rate of death resulting from any cause, encompassing both disease-related and non-disease-related factors
Time frame: 5 years
Cardiovascular death
Rate of death resulting from cardiac diseases
Time frame: 5 years
New-onset arrhythmia
Number of Participants with new-onset arrhythmia
Time frame: 5 years
Sudden cardiac death (SCD)
Number of Participants suffer from sudden cardiac death
Time frame: 5 years
Non-fatal acute myocardial infarction
Number of Participants suffer from non-fatal acute myocardial infarction
Time frame: 5 years
Ischemic stroke
Number of participants suffer from ischemic stroke
Time frame: 5 years
Heart failure hospitalization
The rehospitalization rate of participants due to heart failure
Time frame: 5 years
New York Heart Association (NYHA) Classification
Percentage of participants with changes in NYHA classification
Time frame: 5 years
Kansas City Cardiomyopathy Questionnaire-23 (KCCQ-23)
The KCCQ-23 is a disease-specific health status assessment tool consisting of 23 items that quantify physical limitation, symptoms, self-efficacy, social limitation, and quality of life related to heart failure. Scores range from 0 to 100, with higher scores indicating better health status
Time frame: 5 years
BNP/NT-proBNP
Changes in serum BNP/NT-proBNP concentrations compared to baseline
Time frame: 5 years
Troponin T/I
Changes in serum cardiac troponin concentrations compared to baseline
Time frame: 5 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Jan 2031, 55 months after the start.
Of 82 observational studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 43. This study's planned 55 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardiomyopathy, Hypertrophic →
Second Affiliated Hospital, Zhejiang University, School of Medicine →